Celularity Inc. GXGX
Day range unavailable
52-week range unavailable
- Market cap
- 201.63M
- Shares out
- 12.58M
Key statistics
- Enterprise value
- 0
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 0
- Total debt
- 0
- Return on equity
- 0.00%
- Short % of float
- 6.04%
- 50-day average
- 10.06
- 200-day average
- 10.14
Analyst view
- Strong buy1
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.16.
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 26, 2021 | BTIG | init | — | Buy |
About Celularity Inc.
Celularity Inc., a biopharmaceutical company, develops placental-derived off-the-shelf therapeutic and cellular medicines for cancer, infectious diseases, and degenerative diseases. The company offers Biovance, a human amniotic membrane allograft that provides a protective cover and supports the body's wound healing processes; and Interfyl, a connective tissue matrix for various surgical applications when there is a need to replace and supplement damaged or inadequate integumental tissue. It also offers allogeneic placenta-derived cell therapy product candidates. The company was incorporated in 2016 and is based in Florham Park, New Jersey.
- Sector
- Financial Services
- Industry
- Shell Companies
- Country
- United States
- Website
- celularity.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on GXGX — it syncs with the Stock Master app.